Establishment Labs Holdings (ESTA) Following Higher 2026 Guidance Is It Already Fully Valued

Establishment Labs Holdings (ESTA) reset the conversation around its stock after raising 2026 revenue guidance to more than US$274 million, alongside Q3 2026 results that showed narrower net losses.

That guidance reset has arrived alongside a sharp turn in momentum. Despite a 1-day share price decline of 2.93% to US$68.62 and a 90-day share price return that is down 13.65%, Establishment Labs Holdings has posted a 30-day share price gain of 18.56% and a 3-year total shareholder return above 200%. This points to a story where long term holders have been rewarded even as shorter term sentiment still swings around each new earnings update and outlook change.

Compare this reset in expectations at Establishment Labs Holdings with other healthcare stocks on the move by scanning our hand picked 35 healthcare AI stocks today.

Establishment Labs Holdings now sits between a growth story backed by higher guidance and a stock that some investors see as already pricing in that optimism. Which side does the valuation evidence lean toward next?

Most Popular Narrative: 30% Undervalued

On the analyst consensus Narrative on Simply Wall St, Establishment Labs Holdings screens as undervalued, with a fair value of $98.00 against the last close at $68.62. This puts the focus squarely on whether cash flow and margins can catch up to that gap.

The main factor that has to go right is that Establishment Labs Holdings converts strong surgeon and patient demand for Motiva, Preservé, and the minimally invasive platform into sustained operating leverage and a transition from current net losses to structurally positive free cash flow.

The current valuation reflects a market view that continues to discount Establishment Labs Holdings, even with reported revenue of US$72.0 million in Q3 2026, the first quarter of positive free cash flow of US$5.1 million, and management guidance based on U.S. mix, minimally invasive adoption, and pipeline progress, which collectively underpin a view of the share price as bullish and undervalued.

See why 1 investors see Establishment Labs Holdings as 30% undervalued.

Result: Fair Value of $98.00 (UNDERVALUED)

Still, the Establishment Labs Holdings story can break if ongoing net losses and rising long term debt persist, or if higher margin U.S. and minimally invasive procedures soften.

Find out about the key risks to this Establishment Labs Holdings narrative.

Another View: What Multiples Say About Establishment Labs Holdings

The story looks different when you switch from fair value models to simple sales multiples. Establishment Labs Holdings trades on a P/S of 7.8x, while the US Medical Equipment industry averages 2.9x and close peers sit near 2.8x. The fair ratio is 4.9x, which is the level the market could move toward over time.

That gap suggests investors are already paying a premium for growth that is still ahead of earnings, which raises the question of how much execution risk you are comfortable with before the P/S edges closer to that fair ratio.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Sentiment around Establishment Labs Holdings is split, and that is exactly when your own homework matters most. Move quickly, review the numbers in detail, and weigh the potential upside for yourself by checking the 3 key rewards.

Looking for more investment ideas beyond Establishment Labs Holdings?

You have seen how one story can hinge on valuation and expectations. Do not stop here. Broaden your watchlist with focused idea lists built from hard numbers.

• Target potential bargains early by scanning companies that screen as high quality yet potentially mispriced through the 32 high quality undervalued stocks.
• Prioritise resilience by reviewing a list of solid balance sheet and fundamentals (23 results) that can help you focus on businesses built to handle tougher conditions.
• Get ahead of the crowd by combing through 20 high quality undiscovered gems that may not be on every investor's radar yet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com